|
1）厚生労働省平成25年人口動態統計月報年計（概数）の概況．Available from: http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai13/index.html
|
|
|
|
|
2）Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012; 41: 985-92
|
|
|
|
|
3）Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7: e1000267
|
|
|
|
|
|
4）National Comprehensive Cancer Network (NCCN) Practice Guidelines for pancreatic cancer. [Available at :http://www.nccn.org/clinical asp(free registration is required for login)]
|
|
|
|
|
|
5）Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014; 155: 977-88
|
|
|
|
|
|
6）Satoi S, Yanagimoto H, Toyokawa H, et al. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas. 2011; 40: 426-32
|
|
|
|
|
|
7）Pappas SG, Christians KK, Tolat PP, et al. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? HPB (Oxford). 2014; 16: 70-4
|
|
|
|
|
|
8）Siddiqui AA, Mehendiratta V, Loren D, et al. Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in 241 patients. Dig Dis Sci. 2013; 58: 1744-50
|
|
|
|
|
|
9）Aadam AA, Evans DB, Khan A, et al. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc. 2012; 76: 67-75
|
|
|
|
|
|
10）Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013; 20: 2787-95
|
|
|
|
|
|
11）Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13: 1035-46
|
|
|
|
|
|
12）Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009; 16: 1727-33
|
|
|
|
|
|
13）Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012; 255: 103-8
|
|
|
|
|
|
14）Hirano S, Kondo S, Hara T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Ann Surg. 2007; 246: 46-51
|
|
|
|
|
|
15）日本膵臓学会，編．科学的根拠に基づく膵癌診療ガイドライン2013年版．東京: 金原出版; 2013
|
|
|
|
|
|
16）Takahashi S, Kinoshita T, Konishi M, et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci. 2011; 18: 567-74
|
|
|
|
|
17）Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011; 18: 619-27
|
|
|
|
|
|
18）Sahora K, Kuehrer I, Schindl M, et al. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011; 35: 1580-9
|
|
|
|
|
|
19）Kobayashi M, Mizuno S, Murata Y, et al. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Pancreas. 2014; 43: 350-60
|
|
|
|
|
|
20）Kang CM, Chung YE, Park JY, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012; 16: 509-17
|
|
|
|
|
|
21）Rose JB, Rocha FG, Alseidi A, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014; 21: 1530-7
|
|
|
|
|
|
22）Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012; 118: 5749-56
|
|
|
|
|
|
23）Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012; 152: 851-62
|
|
|
|
|
|
24）Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012; 12: 199
|
|
|
|
|
|
25）Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013; 119: 277-84
|
|
|
|
|
|
26）Barugola G, Partelli S, Crippa S, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012; 203: 132-9
|
|
|
|
|
|
27）Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013; 20: 3794-801
|
|
|
|
|
|
28）Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014; 19: 266-74
|
|
|
|
|
|
29）Donahue TR, Isacoff WH, Hines OJ, et al. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Archives of surgery (Chicago, Ill: 1960). 2011; 146: 836-43
|
|
|
|
|
|
30）Murata Y, Hamada T, Kishiwada M, et al. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepatobiliary Pancreat Sci. 2012; 19: 413-25
|
|
|
|
|
|
31）Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014; 16: 430-8
|
|
|
|
|
|
32）Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-25
|
|
|
|
|
|
33）Tinchon C, Hubmann E, Pichler A, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol. 2013; 52: 1231-3
|
|
|
|
|
|
34）Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013; 42: 1311-5
|
|
|
|
|
|
35）Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011; 254: 882-93
|
|
|
|
|
|
36）Laurence JM, Tran PD, Morarji K, et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011; 15: 2059-69
|
|
|
|
|
|
37）Motoi F, Unno M, Takahashi H, et al. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2014; 21: 148-58
|
|
|
|
|
|
38）Kato H, Usui M, Isaji S, et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013 Mar 14.[Epub ahead of print]
|
|
|
|
|